Clinical trial
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
NCT00092963 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00092963 |
|---|---|
| Title | Study to Test an Approved Product in the Early Treatment of Migraine (0462-065) |
| Official title | A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | MK0462, rizatriptan benzoate / Duration of Treatment: 1day, Comparator: placebo / Duration of Treatment: 1 day |
| Enrollment | 529 |
| Start date | Aug 17, 2004 |
| Primary completion | Jan 14, 2005 |
| Completion | Jan 14, 2005 |
| First posted | Sep 29, 2004 |
| Last update posted | Aug 14, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: